

Members Obtain Free CE Credits from JCP Articles!



Evaluation of Risk Factors for Supratherapeutic Anti-Xa Levels with Treatment-Dose Enoxaparin in Hospitalized Patients Without Severe Renal Impairment

September 2025 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Learners who complete this activity will have enhanced knowledge on determining novel risk factors for supratherapeutic anti-Xa levels to further inform empiric enoxaparin dosing in patients without severe renal impairment. Some patient factors may result in increased risk for supra-therapeutic levels of anti-xa and awareness of potential patient risk factors that may result in increase anti-Xa levels may require reduced enoxaparin dose. This activity will examine the risk factors that may result in increase anti-Xa levels and require dose adjustment.



ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-25-028-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME
ACCREDITED

ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in expanding their knowledge on novel risk factors for supratherapeutic anti-Xa levels.

Learning Objectives

After completing this activity, the learner will be able to:

1. Identify potential risk factors for supratherapeutic anti-Xa levels in patients without severe renal impairment that receive standard treatment-dose of enoxaparin;
2. Evaluate the need for empirically reduced enoxaparin dosing among patients without severe renal impairment;
3. Recognize whether certain corticosteroid doses or durations of therapy translate to an increased risk of supratherapeutic levels of anti-Xa.

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

- Article Selection: John van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.
- Planner: Ahmed Nader, PhD, Senior Director, Clinical Pharmacology, employed at GSK plc, planned the continuing education documentation for this course and all of the relevant financial relationships have been mitigated.
- CE Reviewer: Steven Crosby, MA, BSP, RPh, FASCP, FCP, Associate Dean, Associate Professor, Massachusetts Coll of Pharmacy & Health Sciences, served as the CE Reviewer and has nothing to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 9/1/2025

Expiration Date: 9/1/2028

Online Location:

https://accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14